Citations

Clear

63 citation(s) found for "Smith, Steven".

Reflections on rural community characteristics by an outreach, recruitment, and engagement team
Vassilaki, Maria , Smith, Steven M. , Loftin, Tasha M. , Mohamed, Essa A. , Rethemeier, Nick , Coburn, Ryan P , Graff‐Radford, Jonathan , Petersen, Ronald C. , Boeve, Bradley F. , Lunde, Angela , Lunde, Angela M , Boeve, Brad , Coburn, Ryan P

Mayo Clinic

Journal of Alzheimer’s Disease | June 9, 2026 | Volume: 112 | Issue: 3 | Pages: 1175-1181

10.1177/13872877261454612 | PMID 42261694 Get It

Rural populations are underrepresented in cognitive impairment research and have limited resources for education about brain and cognitive health, Alzheimer's disease and related dementias, or caregiving. As our Outreach, Recruitment, and Engagement team aimed to expand activities into more rural communities, we also wanted to better understand the characteristics of the communities surrounding our center and gain insight into the social exposome of the areas. The goal of the manuscript is to reflect on our experience and share measures that were useful in this effort, which can be further enriched and adjusted by other outreach teams.
Trends in Blood Pressure Control During the COVID‐19 Pandemic: A Study of 17 US Health Systems in the National Patient‐Centered Clinical Research Network Blood Pressure Control Laboratory
Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., Smith, Myra C., Carton, Thomas W. , O'Brien, Emily C, Modrow, Madelaine Faulkner , Wozniak, Gregory , Smith, Steven M., Kappelman, M. D., Ford, D. Patrick, Williams, David A. , VanWormer, Jeffrey J. , Cowell, Lindsay G., Taylor, Bradley W., Chrischilles, EA, Carton, Thomas , O'Brien, Emily , Faulkner Modrow, Madelaine , Rakotz, Michael , Smith, Steven M , Kappelman, Michael D , Ford, Daniel E , Williams, David A , Reynolds Geary, Carol , Litvin, Cara , VanWormer, Jeffrey J , Mosa, Abu Saleh Mohammad , Taylor, Bradley , Chrischilles, Elizabeth A , Pletcher, Mark J , Chamberlain, Alanna M , Cooper‐DeHoff, Rhonda M. , Fontil, Valy , Park, Soo , Shaw, Kathryn M., O’Brien, Emily C. , Rakotz, Michael , Kappelman, Michael D. , Geary, Carol , Taylor, Bradley , Pletcher, Mark J.

Mayo Clinic

Journal of the American Heart Association | April 7, 2026 | Volume: 15 | Issue: 8 | Pages: No page available

10.1161/jaha.125.045694 | PMID 41944158 Get It

Background Reductions in blood pressure (BP) control among patients with hypertension were observed early in the COVID‐19 pandemic. The degree to which BP control may have returned to prepandemic levels is unknown. Methods Individuals aged 18 to 85 years with hypertension from 17 health systems participating in the National Patient‐Centered Clinical Research Network were identified using electronic health record data collected as part of routine care. BP control (percentage of patients whose most recent BP measurement was <140/<90 mm Hg) was estimated in a series of 12‐month rolling measurement periods from 2017 through 2022 (January 1, 2017 through December 31, 2017; April 1, 2017 through March 31, 2018; … January 1, 2022 through December 31, 2022). Differences in average BP control between 2022 (January 1, 2022 through December 31, 2022) and 2019 (January 1, 2019 through December 31, 2019) were estimated overall (adjusted for age, sex, and race and ethnicity) and by race and ethnicity (adjusted for age and sex). Results Our sample included 1 193 314 persons with hypertension in 2019 (48.9% aged 65–85 years, 52.9% men, 66.2% non‐Hispanic White) and 1 499 418 individuals in 2022 (50.6% aged 65–85 years, 47.1% men, 62.7% non‐Hispanic White). The weighted average BP control dropped from 65.3% in 2019 to 61.8% in 2020 and then partially recovered to 62.6% in 2022 (adjusted mean difference, −2.6 percentage points [95% CI, −5.0 to −0.2]). Non‐Hispanic Asian individuals experienced the largest temporal drop in BP control, declining from 68.4% in 2019 to 63.9% in 2022. Conclusions BP control was disrupted during the COVID‐19 pandemic and had not fully rebounded to prepandemic levels by the end of 2022. Continued surveillance is needed to determine whether the decline in BP control will persist and will result in future adverse cardiovascular events.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Glandular Lesions of the Urinary Bladder
Paner, Gladell P. , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang, Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Reis, Henning , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, ISUP Expert Panel On Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

Advances in Anatomic Pathology | August 4, 2025 | Volume: 33 | Issue: 1 | Pages: 1-16

10.1097/pap.0000000000000510 | PMID 40757456 Get It

The Dublin ISUP Consensus Conference covered the proceedings on the best practice recommendations on nonurachal glandular lesions of the urinary bladder, bladder diverticular cancers, and molecular features of bladder and urachal glandular lesions. The conference proceedings on urachal neoplasms (except for their molecular features) are published elsewhere. The rationale for convening this conference was the lack of structured and consented pathologic recommendations in these rare lesions. Consensus by participants was reached on the following statements: (1) intestinal metaplasia with dysplasia is considered to be a precursor to primary bladder adenocarcinoma; (2) dysplasia arising from cystitis glandularis should be reported in terms of focality (focal or nonfocal) and grade (low or high); (3) the term “adenocarcinoma” should only be used for carcinomas showing pure (nonurothelial) morphology and should not be used interchangeably in urothelial carcinoma with “glandular differentiation” because of the pathobiological differences and management implications; (4) the different histologic subtypes of bladder adenocarcinoma should be specified in the report; (5) immunohistochemistry has an ancillary role in the work up of bladder adenocarcinoma versus gastrointestinal or Müllerian-type adenocarcinomas; (6) lymphovascular invasion should be included as a parameter when reporting bladder adenocarcinoma; (7) representative or targeted sampling will be sufficient for bladder diverticulum resection specimens; and (8) molecular analysis in genomic profiling should be performed only in advanced or metastatic bladder and urachal adenocarcinomas for targetable therapy. This report on glandular (nonurachal) lesions of the bladder from the Dublin ISUP consensus conference will serve as a best practice recommendation and as a guide for future research on these relatively rare lesions.
Interobserver Reproducibility of Pelvicalyceal Invasion in Renal Cell Carcinoma Nephrectomies Among Genitourinary Pathologists
Sangoi, Ankur R. , Mubeen, Aysha , Humble, Robert , Wu, Douglas, Amin, Mahul, Aron, Manju , Brimo, Fadi , Chan, Emily , Cheng, Liang, Cheville, John C. , Collins, Katrina, Cornejo, Kristine M. , Downes, Michelle R. , Epstein, Jonathan I. , Hirsch, Michelle S. , Mohanty, Sambit K. , Netto, George J. , Osunkoya, Adeboye O. , Paner, Gladell P. , Rao, Priya, Smith, Steven C. , Tickoo, Satish K. , Tretiakova, Maria , Trpkov, Kiril , Wobker, Sara E. , Tamboli, Pheroze, Zynger, Debra L. , Cheng, Liang , Collins, Katrina , Cheng, Liang , Sangoi, Ankur R , Tretiakova, Maria S , Trpkov, Kiril , Akgül, Mahmut , Pacheco, Richard R. , Acosta, Andrés , Amin, Mahul, Dhillon, Jasreman , Kapur, Payal , Lobo, Anandi , Mehra, Rohit, Saleeb, Rola , Shah, Rajal B. , Shen, Steven S. , Tamboli, Pheroze, Williamson, Sean R.

Mayo Clinic

American Journal of Surgical Pathology | July 30, 2025 | Volume: 49 | Issue: 12 | Pages: 1307-1314

10.1097/pas.0000000000002456 | PMID 40734292 Get It

Pelvicalyceal invasion (PCI) is a relatively novel pT3a staging parameter for renal cell carcinoma (RCC) nephrectomies. While interobserver reproducibility staging studies of sinus/vascular invasion in RCC exist, a similar evaluation for PCI has not been performed. Moreover, in our experience, there is also diagnostic variability in how pathologists interpret PCI. Herein, we explore interobserver reproducibility among genitourinary (GU) pathologists. Twenty hematoxylin and eosin-stained digitized slides from RCCs (all grossly approaching the renal pelvis) were distributed to 31 GU pathologists to classify each as PCI or not PCI based on their respective clinical practices; slides with concomitant sinus/fat/vascular invasion were excluded. Slides were then evaluated for the following 4 morphologic features: tumor abutting renal pelvis, tumor pushing/indenting into the renal pelvis, polypoid configuration of tumor into the renal pelvis, and tumor eroding through renal pelvic urothelium. Interobserver reproducibility was assessed, and the morphologic features were correlated with PCI. Relationships between pathologists’ interpretations, morphologic features, and PCI were evaluated using hierarchical clustering. Although the diagnosis of PCI was relatively uniform with a majority agreement (>67%) reached in 16/20 slides, overall interobserver reproducibility was only moderate (kappa=0.601). While all 4 morphologic features were sensitive for PCI, polypoid configuration of the tumor into the renal pelvis and the tumor eroding through the renal pelvic urothelium were most specific (90%, 100%, respectively). Although we show general consensus among genitourinary pathologists on PCI assessment, clarifying the diagnostic guidelines with specific criteria should be included in pathologic staging systems.
Interobserver reproducibility of hilar soft tissue invasion in testicular germ cell tumours among genitourinary pathologists
Wu, Douglas, Williamson, Sean R. , Pacheco, Richard R. , Acosta, Andrés , Al‐Obaidy, Khaleel I. , Amin, Mahul B. , Berney, Daniel M. , Brimo, Fadi , Cheng, Liang , Cornejo, Kristine M. , Downes, Michelle R. , Epstein, Jonathan I. , Hirsch, Michelle S. , Jiménez, Rafael E. , Kaushal, Seema , Lobo, Anandi , Mehra, Rohit , Mohanty, Sambit K. , Paner, Gladell P. , Reuter, Victor E. , Smith, Steven C. , Tretiakova, Maria , Trpkov, Kiril , Wobker, Sara E. , Tamboli, Pheroze, Zynger, Debra L. , Sangoi, Ankur R , Cheng, Liang , Sangoi, Ankur R. , Williamson, Sean R , Acosta, Andrés M , Al-Obaidy, Khaleel , Berney, Daniel M , Comperat, Eva , Downes, Michelle , Hirsch, Michelle S , Jimenez, Raphael E , Mehra, Rohit , Mohanty, Sambit K , Smith, Steven , Tretiakova, Maria S , Trpkov, Kiril , Zynger, Debra , Sangoi, Ankur R , Cheng, Liang , Sangoi, Ankur R , Akgül, Mahmut , Colecchia, Maurizio , Compérat, Éva , Dhillon, Jasreman , López-Beltrán, Antonio , Rao, Priya , Shah, Rajal B. , Shen, Steven S. , Tamboli, Pheroze

Mayo Clinic

Histopathology | July 4, 2025 | Volume: 87 | Issue: 5 | Pages: 677-686

10.1111/his.15504 | PMID 40611804 Get It

AimsCompared to lymphovascular invasion (LVI), hilar soft tissue invasion (HSTI) is a relatively novel pT2 staging parameter in testicular germ cell tumours (GCT), associated with metastasis at the time of diagnosis and a risk factor for disease relapse. Given diagnostic variability in how pathologists interpret HSTI, herein we explore interobserver reproducibility among genitourinary (GU) pathologists.MethodsTwenty haematoxylin and eosin‐stained digitized slides from testicular GCTs were distributed to 30 GU pathologists to classify each as HSTI or not HSTI based on their respective clinical practices; slides with concomitant LVI were excluded. Slides were then evaluated for the following morphologic features: tumour invasion beyond prominent hilar vessels, tumour invasion beyond the rete, tumour invasion beyond the level parallel to hilar adipose tissue and tumour within (directly touching) hilar adipose tissue. Interobserver reproducibility was assessed, and the morphological features were correlated with HSTI. Relationships between pathologists' interpretations, morphological features and HSTI were evaluated using hierarchical clustering.ResultsAlthough the diagnosis of HSTI was relatively uniform with a majority agreement (>67%) reached in 17/20 slides, overall interobserver reproducibility was only moderate (kappa = 0.50). Morphological features such as invasion beyond the level parallel to hilar adipose tissue and invasion into fat were more sensitive and specific for HSTI, while features such as invasion beyond hilar vessels and invasion beyond rete were less useful.ConclusionsThese findings suggest that more specific defined diagnostic criteria for testicular GCT HSTI are needed.
The Dublin International Society of Urological Pathology (ISUP) Consensus Conference on Best Practice Recommendations on the Pathology of Urachal Neoplasms
Reis, Henning , Cunha, Isabela W. , Amin, Mahul B. , Aron, Manju , Athanazio, Daniel Abensur , Bambury, Richard , Cheng, Liang , Gopalan, Anuradha , Gulmann, Christian, Harris, Carole A. , Jiménez, Rafael E. , Jinzaki, Masahiro , Lal, Priti , Miyai, Kosuke , Netto, George J. , Pan, Chin-Chen, Rhijn, Bas W. van, Smith, Steven C. , Wobker, Sara E. , Paner, Gladell P. , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular, Cheng, Liang , Cheng, Liang , Al-Ahmadie, Hikmat A , Gaisa, Nadine Therese , López-Beltrán, Antonio , Maclean, Fiona M. , Tsuzuki, Toyonori , Aning, Jonathan J. , Guo, Charles Chuanhai , Iyer, Gopa , Kikuchi, Eiji , Pan, Chin‐Chen , Panebianco, Valeria , Siefker-Radtke, Arlene Odelia , Szarvas, Tibor , Kristiansen, Glen , Lesions, the ISUP Expert Panel on Urachal Neoplasms and Urinary Bladder Glandular

Mayo Clinic

American Journal of Surgical Pathology | June 5, 2025 | Volume: 49 | Issue: 11 | Pages: e18-e26

10.1097/pas.0000000000002416 | PMID 40471793 Get It

This manuscript summarizes the first part of the proceedings of the 2023 Dublin ISUP Consensus Conference encompassing the best practice recommendations on the pathology of neoplasms of urachal origin. The rationale for convening this consensus conference was the lack of structured and consented histopathologic recommendations in these rare tumors. Consensus among the meeting participants (n=80) was reached on the following statements: (1) combination of gross, histologic, clinical and imaging findings with exclusion of secondary tumor metastasis are to be used in the diagnosis of urachal carcinoma; (2) the 2022 World Health Organization (WHO) separate criteria for the diagnosis of urachal adenocarcinoma and for nonglandular carcinoma should be applied; (3) specific elements are to be evaluated and recorded in the gross examination of resection specimens containing urachal tumors; (4) sampling considerations for resection specimens containing urachal tumors are advised; (5) participants are against using 5% or 10% cutoff for the extent of intraepithelial carcinoma in urachal mucinous cystic tumor of low malignant potential; (6) use of immunohistochemical markers for the differential diagnosis of urachal adenocarcinomas in transurethral resection (TUR) specimen is considered optional; (7) similar tumor classificatory (nosology) rules for carcinomas arising from bladder mucosa (eg, urothelial carcinoma, squamous cell carcinoma, and neuroendocrine carcinoma) should be applied for nonglandular urachal carcinomas; (8) a new staging approach other than the previously proposed systems should be designed for urachal carcinoma; (9) a system modifying the current Tumor-Node-Metastasis (TNM)/American Joint Committee on Cancer (AJCC) staging system for urinary bladder cancer is considered appropriate for a study in urachal carcinoma; and (10) several histologic elements are to be reported when diagnosing urachal carcinoma in TUR and resection specimens. This report from the Dublin ISUP consensus conference will serve as a practice recommendation for pathologists and as a guide for future standardized reporting protocols and research regarding urachal tumors. In addition, an international database for urachal cancers under the guidance of ISUP is being planned to be established to address pertinent issues in the pathology of urachal cancers.
Cardiovascular Safety of Anti-CGRP Monoclonal Antibodies in Older Adults or Adults With Disability With Migraine
Yang, Seonkyeong , Orlova, Yulia , Smith, Steven M. , Guo, Yi , Chapin, Benjamin A. , Wilson, Debbie L. , Smith, Steven M , Park, Haesuk , Lo‐Ciganic, Wei‐Hsuan

Mayo Clinic

JAMA Neurology | January 6, 2025 | Volume: 82 | Issue: 2 | Pages: 132

10.1001/jamaneurol.2024.4537 | PMID 39761027 Get It

Importance Monoclonal antibodies (mAbs) targeting calcitonin gene-related peptide (CGRP) or its receptor (anti-CGRP mAbs) offer effective migraine-specific preventive treatment. However, concerns exist about their potential cardiovascular risks due to CGRP blockade. Objective To compare the incidence of cardiovascular disease (CVD) between Medicare beneficiaries with migraine who initiated anti-CGRP-mAbs vs onabotulinumtoxinA in the US. Design, Setting, and Participants This retrospective, sequential cohort study was conducted among a nationally representative population-based sample of Medicare claims from May 2018 through December 2020. Data analysis was performed from August to December 2023. This study included fee-for-service Medicare beneficiaries aged 18 years or older with migraine who initiated either anti-CGRP mAbs or onabotulinumtoxinA. Beneficiaries who had a history of myocardial infarction (MI), stroke, cluster headache, malignant cancer, or hospice service within a 1-year baseline period prior to treatment initiation were excluded. To minimize channeling bias from new drug introductions and time-related bias due to the COVID-19 pandemic, 5 cohorts were established, representing sequential 6-month calendar intervals based on the initial prescription or date of index anti-CGRP mAbs or onabotulinumtoxinA use. Exposure Anti-CGRP mAbs vs onabotulinumtoxinA. Main Outcomes and Measures The primary outcome was time to first MI or stroke. Secondary outcomes included hypertensive crisis, peripheral revascularization, and Raynaud phenomenon. The inverse probability of treatment-weighted Cox proportional hazards models were used to compare outcomes between the 2 treatment groups. Results Among 266 848 eligible patients with migraine, 5153 patients initiated anti-CGRP mAbs (mean [SD] age, 57.8 [14.0] years; 4308 female patients [83.6%]) and 4000 patients initiated onabotulinumtoxinA (mean [SD] age, 61.9 [13.7] years; 3353 female patients [83.8%]). Use of anti-CGRP mAbs was not associated with an increased risk of composite CVD events (adjusted hazard ratio [aHR], 0.88; 95% CI, 0.44-1.77), hypertensive crisis (aHR, 0.46; 95% CI, 0.14-1.55), peripheral revascularization (aHR, 1.50; 95% CI, 0.48-4.73), or Raynaud phenomenon (aHR, 0.75; 95% CI, 0.45-1.24) compared with onabotulinumtoxinA. Subgroup analyses by age group and presence of established non-MI or stroke CVD showed similar findings. Conclusions and Relevance In this cohort study, despite initial concerns regarding the cardiovascular effects of CGRP blockade, anti-CGRP mAbs were not associated with an increased risk of CVD compared with onabotulinumtoxinA among adult Medicare beneficiaries with migraine, who were predominantly older adults or individuals with disability. Future studies with longer follow-up periods and in other populations are needed to confirm these findings.
Nonpelvic comorbid symptoms of 45 patients with pain of pelvic venous origin, before and after treatment
Smith, Steven J. , Sichlau, Michael J. , Chen, Brenda, Knight, Dacre , Rowe, Peter C. , Smith, B Holly , Knight, Dacre R T , Rowe, Peter C

Mayo Clinic

Phlebology: The Journal of Venous Disease | August 10, 2024 | Volume: 40 | Issue: 2 | Pages: 66-79

10.1177/02683555241273109 | PMID 39126670 Get It

Objective To report the prevalence and severity of nonpelvic symptoms for patients with venous-origin chronic pelvic pain (VO-CPP) and to describe outcomes after pelvic vein stenting and embolization. Methods We retrospectively reviewed outcomes of 45 women with VO-CPP who underwent treatment with iliac vein stenting and/or embolization. Patients completed symptom-severity questionnaires before and after treatment that assessed for pelvic pain, and multiple other symptoms, including brain fog, anxiety, depression, musculoskeletal pain, fatigue, migraines and more. Results Patient age ranged from 18 to 65 years. The prevalence of common symptoms was as follows: migraines, 69%; brain fog, 76%; anxiety attacks, 58%; excess sweating, 64%; hip pain, 73%; diarrhea, 62%; constipation, 76%; and abdominal bloating, 82%. After treatment, most symptom scores improved by more than 50%; exceptions were excessive sweating (41% improvement) and bloating (47% improvement). Prevalence of individual symptoms that bundle into POTS ranged from 29% to 76%, where symptom improvement ranged from 23% to 59% after treatment. Overlapping individual symptoms characteristic of fibromyalgia and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) were present in 64% to 82% of patients and all improved by 49% to 63% after treatment. Conclusions Pelvic venous flow abnormality is linked causally to a spectrum of interrelated symptoms, of which many can be bundled into named syndromes of unknown cause. With catheter- based treatment of pelvic venous pooling, nonpelvic symptom and syndrome scores improved.
Abstract 10: Trends in Blood Pressure Control With the Covid-19 Pandemic, 2017 to 2022: A Study of 17 US Health Systems in the PCORnet ® Blood Pressure Control Laboratory
Shaw, Kathryn M., Smith, Myra, O’Brien, Emily C. , Chamberlain, Alanna M. , Cooper‐DeHoff, Rhonda M. , Lin, Feng , Fontil, Valy , Carton, Thomas W. , Modrow, Madelaine Faulkner , Wozniak, Gregory , Rakotz, Michael , Smith, Steven M. , Pletcher, Mark J.

Mayo Clinic

Circulation | May 16, 2024 | Volume: 149 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.149.suppl_1.10 Get It

Background: The COVID-19 pandemic resulted in reduced in-person clinic visits and declines in blood pressure (BP) control among patients with hypertension. The purpose of this study was to report on pre- to post-pandemic trends in BP control and related BP metrics through 2022. Methods: We utilized data from 17 US health systems with electronic health record data standardized to the PCORnet ® Common Data Model. Multiple BP control metrics were calculated as a series of quarterly, 12-month rolling measurement periods from 2017 to 2022 (i.e., 1/1/2017-12/31/2017, 4/1/2017-3/31/2018, …, 1/1/2022-12/31/2022). BP control was defined as the percentage of patients with hypertension whose most recent BP measurement at an ambulatory visit was <140/<90 mmHg. Improvement in BP was defined as the percentage of patients with a reduction of 10 mmHg in systolic BP or achievement of systolic BP <140 mmHg during the last 3 months of the measurement period in patients with previously uncontrolled hypertension. Results: In 2022, 1,499,418 persons with hypertension were included (50% 65-85 years old; 47% men; 11% Hispanic, 3% non-Hispanic Asian, 20% non-Hispanic Black, 63% non-Hispanic White). BP control was relatively stable within health systems prior to the COVID-19 pandemic. Worsening of BP control was seen for most health systems in the second quarter of 2020 coinciding with onset of the COVID-19 pandemic (Figure, left panel). The weighted average BP control was 65.3% in 2019, dropped to 61.8% in 2020, and increased to 62.9% in 2021 and 62.6% in 2022. Similar patterns were observed for the improvement in BP metric (Figure, right panel): weighted average 31.4% in 2019, 25.7% in 2020, 29.1% in 2021 and 28.6% in 2022. Conclusion: BP control and improvement in BP decreased substantially during the COVID-19 pandemic. While both metrics improved after 2020, they were still below pre-pandemic levels through 2022. These findings underscore the importance of continued surveillance of BP control and other health impacts of the COVID-19 pandemic.
Initial Antihypertensive Prescribing in Relation to Blood Pressure Among Florida Medicaid and Medicare Recipients in the OneFlorida+ Research Consortium
Smith, Kayla , Keshwani, Shailina , Walsh, Marta , Winterstein, Almut G. , Gurka, Matthew J. , Libby, Anne M. , Hogan, William R. , Pepine, Carl J. , Cooper‐DeHoff, Rhonda M. , Smith, Steven M. , Smith, Kayla M , Walsh, Marta G, Libby, Anne , Hogan, William , Smith, Steven M , Cooper‐DeHoff, Rhonda M.

Mayo Clinic

Hypertension | January 17, 2024 | Volume: 81 | Issue: 2 | Pages: No page available

10.1161/hypertensionaha.123.21901 | PMID 38232142 Get It